Dr. Weisman Quoted in Philadelphia Inquirer Article on Lecanemab

While more study is needed, such blood tests will someday be a valuable tool in determining who will benefit from a drug, said David C. Weisman, a neurologist at Abington Neurological Associates. “These blood-based biomarkers are so powerful,” he said. “They show us an insight to the way the therapies are working. It’s going to be ready for prime time, eventually.”